Clinical Trial News and Research

RSS

Cancer patients with CDI may benefit from DIFICLIR drug

New data presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrate that in cancer patients with CDI, DIFICLIR(fidaxomicin) may offer significant benefits in terms of clinical cure, recurrence and sustained clinical cure.

31 Mar 2012

ChemoCentryx fourth quarter revenues increase to $26.1 million

ChemoCentryx, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2011.

31 Mar 2012

Positive results from Nile's cenderitide Phase 1 trial on chronic heart failure

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure.

29 Mar 2012

FDA extends review period for Almirall and Forest Labs' aclidinium bromide NDA

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for aclidinium bromide, a new long-acting antimuscarinic for the maintenance treatment of Chronic Obstructive Pulmonary Disease.

29 Mar 2012

Nomir announces data from Noveon Laser pivotal trial on onychomycosis

Nomir Medical Technologies, Inc., a leader in novel photobiology and laser therapies, announced today that new data from its landmark pivotal onychomycosis trial first published in the peer-reviewed Journal of the American Podiatric Medical Association (JAPMA) has once again been published in this prestigious journal. The new paper, which reports on a 270 day onychomycosis clinical trial, offers further scientific support for using the Noveon lasers as an effective therapeutic treatment.

29 Mar 2012

OncoSec Medical closes sale of 31,000,000 shares of common stock in registered public offering

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today the closing of the sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering.

29 Mar 2012

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

iCo Therapeutics, a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 Diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema.

29 Mar 2012

Broad Institute, Novartis develop cancer cell line encyclopedia

Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development. Results of the collaboration, published in the journal Nature and released in advance online today, may allow scientists around the world to use this information to improve cancer clinical trial design and further cancer research.

29 Mar 2012

DSMB recommends Bionovo to continue Menerba Phase 3 trial for hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that the Company's independent Data Safety Monitoring Board (DSMB) recommended that the Phase 3 trial of Menerba (MF101) could continue as designed after an initial review of its clinical safety and tolerability data.

29 Mar 2012

Relievant Medsystems secures $30M in Series D equity financing

Relievant Medsystems, Inc., a privately held medical device company pioneering the therapeutic use of basivertebral nerve ablation for the treatment of chronic axial low back pain, announced today that it has secured $30 million in a Series D equity financing to advance and expand the Company's worldwide clinical development programs.

29 Mar 2012

Losing weight and increasing physical activity reduces decline in mobility in obese adults with type 2 diabetes

Weight loss and increased physical fitness nearly halved the decline in mobility in overweight or obese adults with type 2 diabetes, according to four-year results of the Look AHEAD (Action for Health in Diabetes) trial funded by the National Institutes of Health.

29 Mar 2012

Enrollment complete in Aperion Biologics' Z-Lig Anterior Cruciate Ligament Reconstruction Device trial

Aperion Biologics, Inc. announced that it has completed patient enrollment and implantation in the Company's clinical trial of its Z-Lig Anterior Cruciate Ligament Reconstruction (ACLR) Device for the treatment of ligament injuries of the knee.

29 Mar 2012

Identity of probiotics a key factor in determining safety, efficacy of popular ingredient

Regulators, manufacturers and academic researchers from around the world will convene for a two-day workshop on the scientific and regulatory challenges posed by the use of probiotic ingredients in food products. Discussions will focus on how public standards can assist in supporting transparency, consistency and competitiveness of ethical industry players as health claims surrounding probiotic products undergo increased scrutiny.

28 Mar 2012

ACCR designates Georgetown student as early-career scientist

David A. Solomon, who will graduate from Georgetown University School of Medicine this year with M.D. and Ph.D. degrees, has been designated one of four outstanding early-career scientists by the American Association for Cancer Research (AACR) -- a highly prestigious honor. Solomon will present his work at a special symposium, Future Leaders in Basic Cancer Research, on April 2nd at the AACR Annual Meeting 2012 in Chicago.

28 Mar 2012

Magnetic iron oxide nanoparticle-induced hyperthermia can kill cancer cells

Using nanoparticles and alternating magnetic fields, University of Georgia scientists have found that head and neck cancerous tumor cells in mice can be killed in half an hour without harming healthy cells.

28 Mar 2012

First clinical trial to evaluate intravenous antibiotics for CF lung infection

Experts from Bristol and Nottingham are leading a major new national study to investigate whether intravenous antibiotics are effective in killing a common germ that causes dangerous complications in cystic fibrosis (CF) patients.

28 Mar 2012

Therapy Finder - Colorectal Cancer app now available for patients

No one wants to hear the words, "you have colon cancer." For patients diagnosed with an advanced form of the disease, these words can be particularly devastating. The five-year survival rate can be a little as 6 percent. The top-of-mind question becomes, "Which treatment or clinical trial will work for me?"

28 Mar 2012

CRF initiates Harmonizing Outcomes with Revascularization and Stents in AMI II trial

The Cardiovascular Research Foundation (CRF) today announced the initiation of the HORIZONS-AMI II randomized trial, evaluating Promus Element platinum-chromium everolimus-eluting stents versus Omega bare-metal stents in patients with heart attack undergoing primary angioplasty with bivalirudin anticoagulation.

28 Mar 2012

Chocolate for weight loss: Study

The US survey of a population of more than 1000 adults, published as a research letter in the Archives on Internal Medicine, reinforces the idea that chocolate packs heart healthy benefits, despite its high calorie and sugar content. For the study the participants reported eating chocolate an average of twice a week and exercising an average of 3.6 times a week. Their average age was 57.

27 Mar 2012

Sientra receives FDA approval for new silicone gel-filled breast implant

Today, the U.S. Food and Drug Administration approved a silicone gel-filled breast implant manufactured by Sientra Inc. to increase breast size (augmentation) in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age.

27 Mar 2012